Isabella Ciccone, MPH

A national survey showed in its findings that NSAIDs alone and dopamine receptor antagonists are used commonly for treating primary headache disorders in Canadian emergency departments.

In a recent phase 2 study, 6-months of ketogenic diet for people with relapsing multiple sclerosis resulted in a significant reduction in weight, fatigue, and depression, and improved quality of life.

In a phase 3 trial, ULTIMATE I and II, ublituximab resulted in lower annualized relapse rates and fewer brain lesions on MRI than teriflunomide among participants with relapsing multiple sclerosis.

Danielle Kipnis, MA, of Columbia University, discussed the practice of yoga for people with functional neurological disorders from her research and recommendations for future studies in the field.

With diagnosis rates of Alzheimer disease increasing, Tabby Khan, MD, MPH, spoke to the need to focus on cognitive decline in younger patient populations.

Findings from a nonrandomized controlled trial in the Netherlands suggest that sleep time of hospitalized patients may be significantly improved with nonpharmacologic interventions such as the postponement of morning vital sign checks and medication administration rounds from the night to the day shift.

RESCUE-ALS trial, a phase 2 randomized controlled study, showed that ALS disease progression was significantly reduced with CNM-Au8 Treatment.

In a randomized clinical trial, the application of electroacupuncture treatment for insomnia in patients with depression significantly improved the quality of sleep in comparison with sham acupuncture or the control group.

A questionnaire-based study from Saudi Arabia on sleep quality revealed that sleep-related disorders, such as obstructive sleep apnea, are relatively common in patients with Duchenne muscular dystrophy.

Findings from a cross-sectional survey revealed a significant association between depression and a diagnosis of myotonic dystrophy, and that symptoms impacting quality of life are more common in neuromuscular disorders.

A study on ALS progression suggested that tollgate-related prognostic factors have a stronger effect on the time trajectories of passing ALS tollgates in comparison with standard prognostic factors.

In a randomized controlled trial, results demonstrated that acupuncture is to be efficacious in improving insomnia, quality of life, and affective symptoms for patients with ischemic stroke.

Results from pilot program using a VR-based platform suggest medical trainees may benefit from further VR training to gain a complete baseline knowledge of treating lower limb spasticity with onabotulinumtoxinA.

A nonrandomized pilot study demonstrated high adherence rates and acceptability ratings with tele-yoga breathing in patients with ALS, proving that it is a safe and feasible practice.

Adults with myasthenia gravis who contracted COVID-19 were at twice the risk of hospitalization, ICU admission, and death based on data from a recent population-based study.

In an investigation on the effect of treatment with efgartigimod on humoral immune responses to COVID-19 vaccination, the immunization resulted in antigen-specific IgG responses in most patients.

Findings from retrospective study show that repetitive nerve stimulation is a highly sensitive and specific test for the diagnosis of myasthenia gravis in an inpatient setting, with its results being more rapidly available in comparison with antibody testing.

Eplontersen treatment resulted in a significant reduction in transthyretin, neuropathy impairment, and improvement in quality of life in the phase 3 NEURO-TTRansform study of patients with hereditary transthyretin amyloidosis.

Investigators concluded that those receiving avalglucosidase alfa should be tested for antidrug antibodies by physicians who treat Pompe disease and monitor antidrug antibody, according to a recent Sanofi investigation.

ADAPT+ study data on antiacetylcholine receptor antibody-negative patients with generalized myasthenia gravis found improvements in cycle baseline and efficacy with Efgartigimod.

Results from phase 2 RESCUE-ALS trial show that treatment with CNM-Au8 in ALS demonstrated improvement in survival compared to the estimated median survival rate.

Most ambulatory patients had improved pulmonary functions and biomarker outcomes with cipaglucosidase alfa/miglustat that were sustained through a less than 36-month follow-up period.

A trial conducted in Japan showed better functional outcomes for patients with large cerebral infarctions treated with endovascular therapy than those treated with medical care alone, but had more intracranial hemorrhages.

A study presented at the MDS Congress 2022 found an association between migraine and the incidence of Parkinson disease in the middle-aged and older population.

Migraine with aura is suggested as an independent risk factor for atrial fibrillation and that AFib-mediated cardioembolism may play a role with migraines, especially stroke association for some patients.

Results from a pooled analysis extend and support the safety and the tolerability of the use of incobotulinumtoxinA for the treatment of adults with neurological disorders.

Danielle Kipnis, MA, of Columbia University, discussed key components of a yoga program for individuals with functional neurological disorder and from the evaluation, found it feasibility as an intervention.

According to a recommendation from the US Preventive Services Task Force, clinicians should individualize the decision to offer or refer adults without cardiovascular disease risk factors to behavioral counseling interventions to promote a healthy diet and physical activity.

Results from a study provide a link between the association of multiple sclerosis and Epstein-Barr virus which could pave the way in the future for the development of new MS therapies.

Evidence suggests that COVID-19 may induce venous thromboembolism, with an estimated 30% of patients hospitalized with COVID-19 developing the condition.